Previous 10 | Next 10 |
Lipocine to Participate in the Cantor Neurology & Psychiatric Conference Lipocine to Participate in the Cantor Neurology & Psychiatric Conference PR Newswire SALT LAKE CITY , Sept. 27, 2022 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a bioph...
Lipocine ( NASDAQ: LPCN ) on Monday said the company would now focus on applying its drug delivery technology to develop treatments for central nervous system (CNS) disorders. LPCN stock +4.7% to $0.52 in premarket trading. The company will use its proprietary Lip'...
Lipocine Announces Strategic Realignment and Forward Focus on Treating CNS Disorders PR Newswire Company to apply its proprietary Lip'ral oral drug delivery technology to advance a pipeline of differentiated products for Central Nervous System (CNS) disorders Initial...
Lipocine to Present at Ladenburg Thalmann 2022 Healthcare Conference PR Newswire SALT LAKE CITY , Sept. 22, 2022 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on leveraging its proprietary Lip'ral platform to augment th...
Lipocine Announces Favorable Regulatory Pathway on Oral LPCN 1154 for Post-Partum Depression (PPD) PR Newswire FDA agrees with Lipocine establishing LPCN 1154 pathway to efficacy through a pharmacokinetic (PK) bridge to an approved IV infusion brexanolone Lipocine ...
Lipocine press release ( NASDAQ: LPCN ): Q2 GAAP EPS of -$0.04 in-line. Revenue of $0.5M beats by $0.24M . As of June 30, 2022, the company had $37.4 million of unrestricted cash, cash equivalents and marketable investment securities, compared to $46.6 million at D...
Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2022 PR Newswire SALT LAKE CITY , Aug. 8, 2022 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on developing innovative products to treat metaboli...
FDA Clears LPCN 2101 IND for Adult Epilepsy Treatment PR Newswire Phase 2 Photosensitive Epilepsy Study Planned for 2H 2022 SALT LAKE CITY , July 11, 2022 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on developing innovati...
Lipocine (NASDAQ:LPCN) on Tuesday said it had been granted two U.S. patents for its central nervous system and liver programs. LPCN stock +6% to $0.88 in premarket trading. The U.S. Patent and Trademark Office granted LPCN patent 11,337,987 for "Compositions and Methods for Treating...
LIPOCINE GRANTED US PATENTS DIRECTED TO CNS AND LIVER PROGRAMS PR Newswire SALT LAKE CITY , June 14, 2022 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on neuroendocrine and metabolic disorders, today announced that the...
News, Short Squeeze, Breakout and More Instantly...
Lipocine Announces LPCN 1154 Meets Bioequivalence with IV Brexanolone in Pivotal Study PR Newswire Met standard bioequivalence (BE) criteria C max, AUC 0-t , and AUC 0- ∞ C trough criterion was met LPCN 1154 was well tolerat...
Shares of Lipocine Inc. (NASDAQ: LPCN) traded at a new 52-week high today and are currently trading at $8.96. So far today, approximately 78,318 shares have been exchanged, as compared to an average 30-day volume of 32,701 shares. Lipocine Inc., a clinical-stage biopharmaceutical company, foc...
Lipocine Presents 52 Week Results from LPCN 1148 Phase 2 Study in Late Breaking Session at EASL Congress 2024 PR Newswire SALT LAKE CITY , June 10, 2024 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company, today announced that Phase 2 r...